技術指標
指標
數值
方向
MACD(12,26,9)
0.014
中性
RSI(14)
44.679
中性
STOCH(KDJ)(9,3,3)
59.707
中性
ATR(14)
0.022
低波動
CCI(14)
174.394
買入
Williams %R
42.540
買入
TRIX(12,20)
-0.599
賣出
StochRSI(14)
93.433
買入
搜尋
Soligenix Inc
SNGX添加自選
0.371USD
-0.004-0.99%
收盤 07-31 16:00（美東）報價延遲15分鐘
3.91M總市值
虧損本益比TTM
關鍵數據
0.373今開
0.395最高
325.18K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
3.09%換手率
0.375昨收
0.363最低
106.41K成交額
虧損本益比靜
1.26市淨率
0.00%股息率 TTM
-149.35%ROA
6.23052週最高
1.28量比
-8.27M淨利潤
10.52M總股本
-1.4456每股盈餘TTM
1.79Beta
-326.87%ROE
0.28052週最低
8.51%振幅
--毛利率
3.91M總市值
-0.50回報/風險
6.25%風險率
TradingKey Soligenix Inc股票評分
單位: USD 更新時間: 2026-07-31操作建議
Soligenix Inc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名162/385位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為1.75。中期看，股價處於上升通道。近一個月，市場表現一般，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Soligenix Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
Soligenix Inc亮點
亮點風險
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
利潤高增長
公司淨利潤處於行業前列，最新年度總收入0.00美元
估值高估
公司最新PE估值-0.26，處於3年歷史高位
機構減倉
最新機構持股528.92K股，環比減少67.34%
活躍度降低
近期活躍度降低，過去20天平均換手率-0.87
分析師目標
基於
1
分析師
買入
評級
1.750
目標均價
+383.96%
漲幅空間
Soligenix Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
收益預測
分析師評級
基於
1
分析師
買入
評級
1.750
目標均價
+383.96%
漲幅空間
強力買入
買入
持有
賣出
強力賣出
同行比較
496
總數
6
中位數
7
平均值
公司名稱
評級分佈
分析師數
Soligenix Inc
SNGX
1
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
技術指標
移動平均線
指標
數值
方向
MA5
0.367
買入
MA10
0.366
買入
MA20
0.367
買入
MA50
0.443
賣出
MA100
0.690
賣出
MA200
1.030
賣出
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Soligenix Inc簡介
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
公司代碼SNGX
公司Soligenix Inc
CEOSchaber (Christopher J)
網址https://www.soligenix.com/
公司股東
相關品種
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%熱門品種
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
常見問題
Soligenix Inc(SNGX)的當前股價是多少？
Soligenix Inc(SNGX)的當前股價是 0.37。
Soligenix Inc 的股票代碼是什麼？
Soligenix Inc的股票代碼是SNGX。
Soligenix Inc股票的52週最高點是多少？
Soligenix Inc股票的52週最高點是6.23。
Soligenix Inc股票的52週最低點是多少？
Soligenix Inc股票的52週最低點是0.28。
Soligenix Inc的市值是多少？
Soligenix Inc的市值是3.91M。
現在Soligenix Inc(SNGX)的股票是買入、持有還是賣出？
根據分析師評級，Soligenix Inc(SNGX)的總體評級為買入，目標價格為1.75。
Soligenix Inc(SNGX)股票的每股收益（EPS TTM）是多少
Soligenix Inc(SNGX)股票的每股收益（EPS TTM）是-2.14。